Press Release

Non Small Cell Lung Cancer Therapeutics Market Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments Forecast to 2026

The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026. Fortune Business Insights has further predicted the market to exhibit an impressive CAGR of 13.4% between 2019 and 2026 due to exceptional advancements in targeted therapy in recent years. Such high growth can be attributable to the increasing demand for chemotherapy and targeted therapy. Furthermore, advantages of targeted therapy over other alternatives are in plenty. Driven by this, the demand for targeted therapy for diagnosis will increase, which in turn spurs growth in the global non-small cell lung cancer therapeutics market.

 

  • Genentech (F. Hoffmann-La Roche Ltd)
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp.
  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Non Small Cell Lung Cancer by Type
    • Regulatory Scenario by Key Regions
    • Key Industry Developments
    • Pipeline Analysis
    • Overview of Current Advances in R&D for Non Small Cell Lung Cancer Therapeutics
  • Global Non Small Cell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Therapy
      • Targeted Therapy
        • Bevacizumab
        • Dabrafenib/Trametinib
        • Erlotinib Hydrochloride
      • 2.1.4 Osimertinib
        • Others
      • Immunotherapy
        • Durvalumab
        • Nivolumab
        • Atezolizumab
        • Pembrolizumab
      • Chemotherapy
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Market Analysis, Insights and Forecast – By Cancer Type
      • Adenocarcinoma
      • Squamous Cell Carcinoma
      • Large Cell Carcinoma
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa

 

Industry Trends Coronary Guidewires Market: 2020 Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

Growth Lnsight Hormonal Contraceptives Market: 2020 Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

Industry Trends Cataract Surgical Devices Market: 2020 Worldwide Opportunities, Market Share, Key Players and Competitive Landscape

Show More

Betti Stone

Hi, let me cordially welcome you to medical market news. I am Bettie, the chief editor of the website. I have gathered years of experiencing in this website and not only experience but also memories. I have to manage the dynamic editorial team and oversee all strategy and content initiatives. Though I love my job a lot sometimes, I even enjoy the fresh air outside and hence take a walk during a break and re-energise myself.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close